Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pfizer's Phase III ALO-02 Trial Meets Endpoint | Contract Pharma

What are you searching for?

Sign in

Pfizer’s Phase III ALO-02 Trial Meets Endpoint

Demonstrates statistically significant benefit

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pfizer reported top-line results from a Phase III study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic low back pain. ALO-02 met the primary efficacy endpoint, demonstrating a statistically significant benefit from placebo. The most common adverse events with ALO-2 during the double-blind period in this study were nausea, vomiting and diarrhea.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics